AdvisorShares Investments LLC Boosts Stock Position in Pasithea Therapeutics Corp. $KTTA

AdvisorShares Investments LLC boosted its holdings in shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA) by 261.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 193,547 shares of the company’s stock after purchasing an additional 140,000 shares during the quarter. AdvisorShares Investments LLC’s holdings in Pasithea Therapeutics were worth $140,000 at the end of the most recent quarter.

Pasithea Therapeutics Trading Up 15.8%

Shares of KTTA opened at $0.84 on Friday. The firm has a market cap of $6.23 million, a price-to-earnings ratio of -0.11 and a beta of 0.27. The stock has a 50 day moving average of $0.76 and a 200-day moving average of $0.86. Pasithea Therapeutics Corp. has a 52 week low of $0.65 and a 52 week high of $4.35.

Pasithea Therapeutics (NASDAQ:KTTA) last issued its earnings results on Thursday, August 14th. The company reported ($0.66) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Pasithea Therapeutics in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Pasithea Therapeutics currently has a consensus rating of “Sell”.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.